Ramucirumab inhibits VEGFR‐2 phosphorylation mediated by VEGF and then inhibits activation of its downstream signaling molecules (phosphoinositide phospholipase C‐γ, MAPK), hampering the migration and proliferation of tumor cells.229. This evidence concerns the gene KDR and neoplasm.